Stock 002900 HARBIN MEDISAN PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Harbin Medisan Pharmaceutical Co., Ltd.

Equities

002900

CNE1000032V9

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 03:30:00 30/04/2024 am IST 		5-day change 1st Jan Change
9.92 CNY -0.70% Intraday chart for Harbin Medisan Pharmaceutical Co., Ltd. +0.51% -27.33%
26/04 Harbin Medisan Pharmaceutical Co., Ltd. Proposes Final Dividend for 2023 CI
26/04 Medisan Pharma's Potassium Chloride Injection Passes Drug Regulator's Evaluation MT

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 3,825 3,702 2,866 6,453 4,229 4,228
Enterprise Value (EV) 1 2,677 2,688 2,113 5,829 3,591 3,897
P/E ratio 18.6 x 20.9 x 103 x 18.4 x 137 x 56.9 x
Yield 5.38% 2.35% 0.86% 1.54% 0.73% -
Capitalization / Revenue 1.76 x 1.76 x 2.14 x 6.82 x 4.11 x 3.56 x
EV / Revenue 1.23 x 1.28 x 1.58 x 6.16 x 3.49 x 3.28 x
EV / EBITDA 11.8 x 11.2 x 32.5 x -96.2 x 57.8 x 33.8 x
EV / FCF 20.5 x 34.9 x -9.63 x -207 x 47.8 x -16.8 x
FCF Yield 4.88% 2.86% -10.4% -0.48% 2.09% -5.95%
Price to Book 1.96 x 2.02 x 1.61 x 3.07 x 2.07 x 1.78 x
Nbr of stocks (in thousands) 3,16,600 3,10,026 3,09,785 3,09,785 3,09,785 3,09,745
Reference price 2 12.08 11.94 9.250 20.83 13.65 13.65
Announcement Date 23/04/19 23/04/20 27/04/21 26/04/22 25/04/23 25/04/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 2,173 2,102 1,339 945.8 1,028 1,187
EBITDA 1 227.1 240.1 65.01 -60.6 62.16 115.5
EBIT 1 155 163.8 -14.56 -150 -31.91 17.05
Operating Margin 7.13% 7.79% -1.09% -15.86% -3.1% 1.44%
Earnings before Tax (EBT) 1 249.1 228.2 33.16 452.9 40.07 81.37
Net income 1 205.8 177.2 29.32 351 30.21 73.66
Net margin 9.47% 8.43% 2.19% 37.11% 2.94% 6.21%
EPS 2 0.6500 0.5700 0.0900 1.130 0.1000 0.2400
Free Cash Flow 1 130.7 77 -219.5 -28.2 75.09 -231.8
FCF margin 6.02% 3.66% -16.39% -2.98% 7.3% -19.53%
FCF Conversion (EBITDA) 57.57% 32.07% - - 120.79% -
FCF Conversion (Net income) 63.52% 43.46% - - 248.55% -
Dividend per Share 2 0.6500 0.2800 0.0800 0.3200 0.1000 -
Announcement Date 23/04/19 23/04/20 27/04/21 26/04/22 25/04/23 25/04/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 1,148 1,013 752 624 637 331
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 131 77 -219 -28.2 75.1 -232
ROE (net income / shareholders' equity) 10.7% 9.11% 1.46% 17.9% 1.27% 3.34%
ROA (Net income/ Total Assets) 4.12% 3.95% -0.35% -3.38% -0.63% 0.32%
Assets 1 4,990 4,485 -8,305 -10,383 -4,804 23,230
Book Value Per Share 2 6.150 5.920 5.730 6.780 6.590 7.690
Cash Flow per Share 2 1.430 1.520 2.140 1.710 3.880 3.560
Capex 1 78.4 199 146 73.9 89.2 300
Capex / Sales 3.61% 9.45% 10.89% 7.82% 8.68% 25.24%
Announcement Date 23/04/19 23/04/20 27/04/21 26/04/22 25/04/23 25/04/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
HARBIN MEDISAN PHARMACEUTICAL CO., LTD. Stock Harbin Medisan Pharmaceutical Co., Ltd.
-27.33% 424M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.08% 662B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 546B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.77% 359B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.97% 323B
ABBVIE INC. Stock AbbVie Inc.
+5.69% 290B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 234B
NOVARTIS AG Stock Novartis AG
+3.65% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 194B
AMGEN INC. Stock Amgen Inc.
+8.08% 167B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 002900 Stock
  4. Financials Harbin Medisan Pharmaceutical Co., Ltd.